Amarin (AMRN) Competitors $15.39 -0.59 (-3.69%) Closing price 04:00 PM EasternExtended Trading$15.47 +0.08 (+0.51%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. AVDL, EVO, PAHC, TLRY, CVAC, COLL, CALT, XERS, ELVN, and PHVSShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Avadel Pharmaceuticals (AVDL), Evotec (EVO), Phibro Animal Health (PAHC), Tilray Brands (TLRY), CureVac (CVAC), Collegium Pharmaceutical (COLL), Calliditas Therapeutics AB (publ) (CALT), Xeris Biopharma (XERS), Enliven Therapeutics (ELVN), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Avadel Pharmaceuticals Evotec Phibro Animal Health Tilray Brands CureVac Collegium Pharmaceutical Calliditas Therapeutics AB (publ) Xeris Biopharma Enliven Therapeutics Pharvaris Avadel Pharmaceuticals (NASDAQ:AVDL) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation. Do institutionals & insiders have more ownership in AVDL or AMRN? 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 5.2% of Avadel Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, AVDL or AMRN? Avadel Pharmaceuticals has higher earnings, but lower revenue than Amarin. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$169.12M8.50-$48.83M-$0.03-493.67Amarin$228.61M1.39-$82.18M-$3.67-4.19 Do analysts recommend AVDL or AMRN? Avadel Pharmaceuticals presently has a consensus target price of $19.67, suggesting a potential upside of 32.79%. Amarin has a consensus target price of $12.00, suggesting a potential downside of 22.03%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is AVDL or AMRN more profitable? Avadel Pharmaceuticals has a net margin of -1.32% compared to Amarin's net margin of -47.22%. Avadel Pharmaceuticals' return on equity of -3.73% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-1.32% -3.73% -1.73% Amarin -47.22%-21.18%-15.00% Which has more risk and volatility, AVDL or AMRN? Avadel Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Amarin has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Does the media favor AVDL or AMRN? In the previous week, Avadel Pharmaceuticals had 2 more articles in the media than Amarin. MarketBeat recorded 4 mentions for Avadel Pharmaceuticals and 2 mentions for Amarin. Amarin's average media sentiment score of 0.96 beat Avadel Pharmaceuticals' score of 0.54 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAvadel Pharmaceuticals beats Amarin on 14 of the 16 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$330.90M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E RatioN/A20.9030.1925.84Price / Sales1.39390.30474.98187.82Price / CashN/A43.2325.7828.79Price / Book0.659.649.425.99Net Income-$82.18M-$54.08M$3.27B$265.29M7 Day Performance-4.82%2.62%2.05%2.53%1 Month PerformanceN/A4.05%3.58%0.92%1 Year Performance22.41%9.48%30.09%18.70% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.2962 of 5 stars$15.39-3.7%$12.00-22.0%+27.1%$330.90M$228.61M0.00360AVDLAvadel Pharmaceuticals2.6594 of 5 stars$13.48-1.5%$18.67+38.5%-7.6%$1.31B$221.08M-449.3370EVOEvotec1.5238 of 5 stars$3.68-2.1%$5.40+46.7%+8.7%$1.31B$862.40M0.004,827PAHCPhibro Animal Health3.4286 of 5 stars$31.25+1.9%$24.40-21.9%+55.0%$1.27B$1.02B40.061,940News CoverageUpcoming EarningsTLRYTilray Brands2.4756 of 5 stars$1.14+10.7%$1.92+68.1%-40.4%$1.25B$821.31M-0.492,842Analyst ForecastGap UpCVACCureVac4.6285 of 5 stars$5.45-0.5%$6.83+25.4%+64.4%$1.22B$579.18M5.92880Earnings ReportCOLLCollegium Pharmaceutical2.3222 of 5 stars$38.19+1.2%$42.33+10.8%+7.9%$1.20B$631.45M36.72210News CoverageCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180XERSXeris Biopharma3.4158 of 5 stars$7.36-4.2%$6.58-10.6%+169.1%$1.19B$203.07M-35.05290News CoveragePositive NewsAnalyst RevisionELVNEnliven Therapeutics2.8149 of 5 stars$19.75-2.3%$41.20+108.6%-9.3%$1.17BN/A-9.8850PHVSPharvaris2.9484 of 5 stars$22.16-0.6%$35.60+60.6%+29.5%$1.16BN/A-6.6030Positive News Related Companies and Tools Related Companies Avadel Pharmaceuticals Alternatives Evotec Alternatives Phibro Animal Health Alternatives Tilray Brands Alternatives CureVac Alternatives Collegium Pharmaceutical Alternatives Calliditas Therapeutics AB (publ) Alternatives Xeris Biopharma Alternatives Enliven Therapeutics Alternatives Pharvaris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access